UroSEEK gene panel for bladder cancer surveillance

Cancer of the urinary bladder is incredibly aggressive and is highly resistant to many of today’s currently available cancer therapies. In 2019 alone, an estimated 80,470 newly diagnosed cases of bladder cancer (BCa) and 17,670 deaths from BCa is expected to occur in 2019 in the United States (1). In addition, since 2002, the absolute numbers of cases and deaths from BCa have increased by 45% and 35%, respectively (2,3).